Vitreous hemorrhage during GLP-1 receptor agonist treatment.

Kim DS, Latollari A, Khaimova R

Journal of the American Pharmacists Association : JAPhA27 Feb 2023Cited by 3 (Europe PMC)

PMID36966088DOI10.1016/j.japh.2023.02.018PepBankPUB-36966088

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesEfficacy outcome
In a man with diabetes, HbA1c decreased to 7.3% after dulaglutide was restarted and increased.
In plain wordsIn one man with diabetes, HbA1c fell during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Increased to 4.5 mg weekly · 12 weeksAs given in this study (human).
Measurements
HbA1c at baseline
8.8%
before restart
HbA1c at week 12 after reinitiation
7.3%
dulaglutide dose increased to 4.5 mg weekly
Source sentences
Summary
In absence of intolerance, the dulaglutide dose was gradually maximized to 4.5 mg weekly and HbA1c decreased to 7.3% and random BG to 121 mg/dL at week 12 since reinitiation.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline laboratory test results included hemoglobin A1c (HbA1c) of 8.8% and random blood glucose (BG) of 280 mg/dL.
Report a problemFND-3696608801
02HumanCase report or seriesEfficacy outcome
In a man with diabetes, random glucose decreased to 121 mg/dL after dulaglutide was restarted and increased.
In plain wordsIn one man with diabetes, random blood glucose fell during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseRandom blood glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Increased to 4.5 mg weekly · 12 weeksAs given in this study (human).
Measurements
Random blood glucose at baseline
280 mg/dL
before restart
Random blood glucose at week 12 after reinitiation
121 mg/dL
dulaglutide dose increased to 4.5 mg weekly
Source sentences
Summary
In absence of intolerance, the dulaglutide dose was gradually maximized to 4.5 mg weekly and HbA1c decreased to 7.3% and random BG to 121 mg/dL at week 12 since reinitiation.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline laboratory test results included hemoglobin A1c (HbA1c) of 8.8% and random blood glucose (BG) of 280 mg/dL.
Report a problemFND-3696608802
03HumanCase report or seriesSafety outcome
A man with severe diabetic retinopathy developed vitreous hemorrhage during dulaglutide treatment, with unclear causation.
In plain wordsOne man developed bleeding inside the eye during dulaglutide treatment, but the cause was unclear.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVitreous hemorrhage
Study
n = 1
Outcome group
Adverse events · Eye
Studied dose
Dose not stated · 17 weeksAs given in this study (human).
Source sentences
Summary
At week 17 of therapy, the patient presented to the emergency department with a 1-day history of vision loss in the left eye and was diagnosed as having vitreous hemorrhage. The etiology for vitreous hemorrhage is unclear and may be a spontaneous episode.
1 context sentence(design, population, supporting numbers)
Summary · context
A 64-year-old African American male with a past medical history of T2DM and severe diabetic retinopathy for 4 years was restarted on dulaglutide 1.5 mg weekly after being off therapy for 3 months.
Report a problemFND-3696608803
04HumanCase report or seriesSafety outcome
The man reported no recurrent vitreous hemorrhage symptoms after dulaglutide reinitiation.
In plain wordsThe man reported no repeat eye bleeding symptoms after dulaglutide restarted.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableRecurrent hemorrhage symptoms
Study
n = 1
Outcome group
Adverse events · Eye
Studied dose
1.5 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
After 4 weeks of reinitiation, the patient denied any recurrent symptoms of vitreous hemorrhage or worsening diabetic retinopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
In discussion with the patient and the ophthalmologist, dulaglutide was restarted at 1.5 mg once weekly.
Report a problemFND-3696608804
05HumanCase report or seriesSafety outcome
The man's most recent eye examination showed no change in diabetic retinopathy after dulaglutide reinitiation.
In plain wordsThe man's latest eye examination showed no change in diabetic retinopathy after dulaglutide restarted.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeDiabetic retinopathy progression
Study
n = 1
Outcome group
Adverse events · Eye
Studied dose
1.5 mg once weeklyAs given in this study (human).
Source sentences
Summary
The most recent ophthalmology evaluation indicated no change in diabetic retinopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
In discussion with the patient and the ophthalmologist, dulaglutide was restarted at 1.5 mg once weekly.
Report a problemFND-3696608805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.